News
Press Releases

Thursday, February 23, 2017

Positive Results From Pre-Clinical Studies Sponsored by CardioCell Post in the American Heart Association’s Journal “Circulation Research”

SAN DIEGO — Feb. 23, 2017 — Results from an acute myocardial infarction and an ischemic cardiomyopathy pre-clinical study sponsored by CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, are the subject of a peer-reviewed paper published in the American Heart Association’s journal “Circulation Research.” Entitled “Intravenously-Delivered Mesenchymal Stem…
Read Entire Article

Thursday, November 17, 2016

Positive Results From Study Sponsored by CardioCell Post in the American Heart Association’s Journal “Circulation Research”

SAN DIEGO — Nov. 17, 2016 — Results from a study sponsored by CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, form the basis for a peer-reviewed paper published in the American Heart Association’s journal “Circulation Research.” Entitled “Intravenous (IV) Allogeneic Mesenchymal Stem Cells for Non-Ischemic Cardiomyopathy: Safety and…
Read Entire Article

Wednesday, October 12, 2016

Independent Data Safety Monitoring Board (DSMB) Unanimously Recommends CardioCell’s Heart Failure Studies Continue

SAN DIEGO – Oct. 12, 2016 – CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces an independent data safety monitoring board (DSMB) concluded its review of the company-sponsored Phase IIa clinical trial results and votes unanimously to recommend studies continue. The trial, “Safety and Efficacy of Intravenous (IV)…
Read Entire Article

Monday, August 29, 2016

European Society of Cardiology (ESC) Congress Presentation Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Acute Myocardial Infarction (AMI)

ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 29, 2016 – Study sponsor CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces data from its pre-clinical study “Mesenchymal stem cells grown under chronic hypoxia traffic to regions of myocardial infarction, suppress splenic natural killer cells, and…
Read Entire Article

Sunday, August 28, 2016

CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications

ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 28, 2016 – Study sponsor CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces data from its Phase IIa clinical trial “Safety and Efficacy of Intravenous Infusion of Ischemia-Tolerant Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Cardiomyopathy”…
Read Entire Article

European Society of Cardiology (ESC) Congress Poster Session Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Chronic Ischemic Cardiomyopathy

ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 28, 2016 – Study sponsor CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces data from its pre-clinical study “Mesenchymal stem cells grown under chronic hypoxia improve LV function and inhibit adverse remodeling in mice with chronic ischemic…
Read Entire Article

Tuesday, August 16, 2016

Three CardioCell-Sponsored Studies Reveal Results at the European Society of Cardiology (ESC) Congress 2016

ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 16, 2016 – CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces results from three of its sponsored studies are accepted for presentation at ESC Congress. Each study – a Phase IIa clinical trial and two pre-clinical studies…
Read Entire Article

Tuesday, June 14, 2016

European Society of Cardiology (ESC) Selects CardioCell’s Heart Failure (HF) Study Results for ESC Congress 2016 Late-Breaking Science Session

SAN DIEGO — June 14, 2016 — CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces that the European Society of Cardiology (ESC) has accepted data from CardioCell’s Phase IIa heart failure (HF) study for an ESC Congress 2016 “Hot Line” Late-Breaking Science Session, a track that features innovative…
Read Entire Article

Tuesday, April 19, 2016

CardioCell Completes Enrollment for a Phase IIa Clinical Trial Using Its Stem Cells for Participants With Chronic Heart Failure

SAN DIEGO — April 19, 2016 — CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, fulfills enrollment for its Phase IIa chronic heart failure (HF) clinical trial. A total of 23 randomized participants were enrolled at study centers at Emory University in Atlanta, MedStar Washington Hospital Center in Washington,…
Read Entire Article
Older Entries »